Renal actions of the new angiotensin-converting enzyme inhibitor benazepril hydrochloride.
Renal actions of the new angiotensin-converting enzyme inhibitor benazepril hydrochloride were evaluated in comparison to enalapril in the anesthetized dog. Intravenous injection of either 0.4 mg/kg benazepril hydrochloride or enalapril significantly reduced mean arterial pressure (MAP) and significantly increased renal blood flow and glomerular filtration rate over a 2 hr period. Urine volume and sodium excretion increased, while urine osmolality decreased following i.v. injection of either benazepril hydrochloride or enalapril. The results presented in this study demonstrate that the new and structurally novel converting enzyme inhibitor benazepril hydrochloride has potent actions on renal function which are essentially identical to those of enalapril.
Levens
N R
NR
Research Department, Ciba-Geigy Corporation, Summit, NJ 07901.
D000803:Angiotensin I / Q000494:pharmacology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D001552:Benzazepines / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D004285:Dogs; D004656:Enalapril / Q000494:pharmacology; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D066298:In Vitro Techniques; D007668:Kidney / Q000187:drug effects*; D007677:Kidney Function Tests; D008297:Male; D012083:Renin / Q000097:blood
D000806:Angiotensin-Converting Enzyme Inhibitors; D001552:Benzazepines; D004656:Enalapril; D000803:Angiotensin I; D012083:Renin; C044946:benazepril